RNS Number:1992Q
Hikma Pharmaceuticals Plc
26 January 2007



                 Hikma completes its acquisition of Ribosepharm

LONDON, 26 January 2007 - Following the announcement made by Hikma
Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the multinational
pharmaceuticals group, on 22 January 2007 regarding the acquisition of
Ribosepharm GmbH, Hikma today announces that the transaction has been completed.

Samih Darwazah, Chairman & CEO of Hikma, commented: "The acquisition of
Ribosepharm provides us with an excellent platform from which to enter the large
and fast-growing oncology market, which is forecast to become the second largest
within the pharmaceutical industry by 2010. Ribosepharm has a strong position in
Germany, one of the largest European oncology markets, and significant
distribution capabilities. We will be able to draw on its experience in the
field of oncology and use its expertise to expand into other oncology markets in
Europe, as well as into the United States and the MENA region. We look forward
to working with Dr. Kudielka, Ribosepharm's Managing Director, and his
experienced team."

                                    - ENDS -
Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director              +44 20 7399 2760

Brunswick Group

Jon Coles / Justine McIlroy / Alex Tweed                +44 20 7404 5959

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ("MENA") region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.

About Ribosepharm

Ribosepharm is a well-established and successful oncology company, specialising
in the marketing and distribution of branded generic injectable oncology
products both to private practices and hospitals in Germany.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
ACQBQLFLDFBZBBZ
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.